Journals / Turkish Journal of Urology / 2017 / Cilt: 43 - Sayı: 2

Emphysematous pyelonephritis: Changing trend of clinical spectrum, pathogenesis, management and outcome

Amfizematöz piyelonefrit: Klinik spektrum, patogenez, tedavi ve sonuçta değişen eğilim

Pages
202–209
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Emphysematous pyelonephritis managementrequires multidisciplinary collaboration including hydration and electrolyte management, broadspectrum antibiotics, strict glycaemic control, effective urinary drainage and lastly it may require emergencynephrectomy as a salvage procedure.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To highlight changing trend of clinical spectrum, comparing management options and predictorsof outcome of emphysematous pyelonephritis.Material and methods: This study included patients who were diagnosed as emphysematous pyelonephritisbetween August, 2001 to July, 2015.
📊
Key Findings & Data:Patients were classified as “responders” and “non-responders”.Results: We studied a total of 74 patients and categorised them as responders (62 patients) and non-responders(12 patients).
💡
Conclusion & Impact:Emphysematous pyelonephritis managementrequires multidisciplinary collaboration including hydration and electrolyte management, broadspectrum antibiotics, strict glycaemic control, effective urinary drainage and lastly it may require emergencynephrectomy as a salvage procedure.
🔬Design:Research Article
📍Scope:2001 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To highlight changing trend of clinical spectrum, comparing management options and predictorsof outcome of emphysematous pyelonephritis.Material and methods: This study included patients who were diagnosed as emphysematous pyelonephritisbetween August, 2001 to July, 2015. We excluded other possible causes of gas in renal system. Baselinepatient characteristics, clinical spectrum, serum and urinary biochemical parameters, radiological findings,management and outcomes were recorded. Patients were classified as “responders” and “non-responders”.Results: We studied a total of 74 patients and categorised them as responders (62 patients) and non-responders(12 patients). Women outnumbered men constituting 62.16% of the study population (M: F; 1: 1.6). Feverwas the most common presenting symptom followed by flank pain. Diabetes mellitus (85.14%) was themost common comorbidity followed by urolithiasis (32.43%). Escherichia coli was the commonest organismgrown in urine culture (79.73%). Non-responders had distinct laboratory findings relative to respondersas low hemoglobin (7.8±2.1/11.2±3.2 g/dL; p=0.0007), thrombocytopenia (91.67% vs. 11.29%; p=0.0001),proteinuria >3 g/L (50% vs. 6.45%; p=0.0008) and positive blood culture (100% vs. 67.74%; p=0.0288).Conclusion: Advanced age, higher body mass index, renal impairment, thrombocytopenia, altered sensorium,shock at presentation can be used as scores for poor prognosis. Emphysematous pyelonephritis managementrequires multidisciplinary collaboration including hydration and electrolyte management, broadspectrum antibiotics, strict glycaemic control, effective urinary drainage and lastly it may require emergencynephrectomy as a salvage procedure.

Özet

Amaç: Amfizematöz piyelonefritte tedavi seçenekleri ve sonucu öngören parametreleri karşılaştırarak klinik spektrumda değişen eğilimi vurgulamak Gereç ve yöntemler: Bu çalışmaya Ağustos 2001 ile Temmuz 2015 arasında amfizematöz piyelonefrit tanısı konmuş hastalar dahil edilmiştir. Renal sistemde gaz oluşturacak diğer nedenler dışlanmıştır. Başlangıçta hasta karakteristik özellikleri, klinik spektrum, serum ve idrar biyokimyasal parametreleri,radyolojik bulgular, tedavi ve sonuç kaydedilmiştir. Hastalar “yanıt verenler” ve “yanıt vermeyenler” olarak sınıflandırılmıştır. Bulgular: Toplam 74 hasta incelendi ve bu olgular yanıt verenler (n=62) ve yanıt vermeyenler (n=12) olarak kategorize edildi. Kadınlar erkeklerden daha fazla olup çalışma popülasyonunun %62,6’sını oluşturmaktaydı (E: K; 1: 1,6). Ateş en sık başvuru semptomu olup ardından yan ağrısı gelmekteydi. Birlikte en çok diabetes mellitus (%85,14) ardından taş hastalığı (%32,43) gelmekteydi. İdrar kültüründe en çok Escherichia coli (%79,73) üremişti. Yanıt vermeyenler, yanıt verenlerden belirgin olmak üzere farklı laboratuvar bulgularına sahipti (düşük hemoglobin: 7,8±2,1/11,2±3,2 g/dL; p=0,0007), trombositopeni: %91,67’e karşın %11,29; p=0,0001; proteinüri; >3 gm/L; %50’ye karşın %6,45; p=0,0008 ve pozitif kan kültürü: %100’e karşın %67,74; p=0,0288). Sonuç: İleri yaş, daha yüksek vücut kitle indeksi, böbrek fonksiyon bozukluğu, trombositopeni, değişen sensoriyum, başvuruda şok kötü prognozun skorlanmasında kullanılabilir. Amfizematöz piyelonefritin tedavisi, hidrasyon ve elektrolit tedavisi, geniş spektrumlu antibiyotikler, sıkı glisemik kontrol, etkili üriner drenaj ve sonunda kurtarma prosedürü olarak acil nefrektomiyi gerektirebilir

🔖

Cite This Article

BANSAL, A., KUMAR, M., SANKHWAR, S., PURKAİT, B., SOKHAL, A. K., JHANWAR, A., KAURA, K. S. (2022). Emphysematous pyelonephritis: Changing trend of clinical spectrum, pathogenesis, management and outcome. Turkish Journal of Urology, Cilt: 43 - Sayı: 2, 202–209. https://ajindex.com/articles/654607

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Somani BK, Nabi G, Thorpe P, Hussey J, Cook J, N’Dow J, et al. Re: is percutaneous drainage the new gold standard in the management of emphysematous pyelonephritis? Evidence from a systematic review. J Urol 2009;181:411-2. [CrossRef] Kapoor R, Muruganandham K, Gulia AK, Singla M, Agrawal S, Mandhani A, et al. Predictive factors for mortality and need for nephrectomy in patients with emphysematous pyelonephritis. BJU Int 2010;105:986-9. [CrossRef] Ahmad M, Dakshinamurty KV. emphysematous renal tract disease due to Aspergillis fumigatis. J Assoc Physicians India 2004;52:495-7.
  2. Sultana SR, McNeille SA, Phillips G, Byrne D. Candidal urinary tract infection as a course of pneumaturia. J R Coll Surg Edinb 1998;43:198-9.
  3. Lu YC, Hong JH, Chiang BJ, Pong YH, Hsueh PR, Huang CY, Pu YS. Recommended initial antimicrobial therapy for emphysematous pyelonephritis: 51 cases and 14-year-experience of a tertiary referral center. Medicine 2016;95:e3573. Liao HW, Chen TH, Lin KH, Lin HH, Hsu YH, Hou CC, et al. Emphysematous pyelonephritis caused by Bacteroides fragilis. Nephrol Dial Transplant 2005;20:2575-7. [CrossRef] Olvera-Posada D, Armengod-Fischer G, Vázquez-Lavista LG, Maldonado-Ávila M, Rosas-Nava E, Manzanilla-García H, et al. Emphysematous pyelonephritis: multicenter clinical and therapeutic experience in Mexico. Urology 2014;83:1280-4. [CrossRef] Ubee SS, McGlynn L, Fordham M. Emphysematous pyelonephritis. BJU Int 2011;107:1474-8. [CrossRef] Chen MT, Huang CN, Chou YH, Huang CH, Chiang CP, Liu GC. Percutaneous drainage in the treatment of emphysematous pyelonephritis, 10-year experience. J Urol 1997;157:1569-73. [CrossRef] Shokeir AA, El-Azab M, Mohsen T, El-Diasty T. Emphysematous pyelonephritis: a 15-year experience with 20 cases. Urology 1997;49:343-6. [CrossRef] WHO Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63. [CrossRef] Huang JJ, Tseng CC. Emphysematous pyelonephritis: clinicoradiological classification, management, prognosis, and pathogenesis. Arch Intern Med 2000;160:797805. Aswathaman K, Gopalakrishnan G, Gnanaraj L, Chacko NK, Kekre NS, Devasia A. Emphysematous pyelonephritis: Outcome of conservative management. Urology 2008;71:1007-9. [CrossRef] Pontin AR, Barnes RD, Joffe J, Kahn D. Emphysematous pyelonephritis in diabetic patients. Br J Urol 1995;75:71-4. [CrossRef] Turney JH. Renal conservation for gas forming infections. Lancet 2000;355:770-